Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 28;14(1):206-212.
doi: 10.21037/jgo-22-1169. Epub 2023 Feb 1.

Clinical significance and changes to the immune microenvironment of colorectal cancer patients with liver metastasis

Ting Wang  1 , Long Tang  2 , Bing Ouyang  3 , Xingyue Chen  1 , Jun Qi  4
Affiliations

Clinical significance and changes to the immune microenvironment of colorectal cancer patients with liver metastasis

Ting Wang et al. J Gastrointest Oncol. .

Abstract

Background: Liver metastasis is common in colorectal cancer patients. Immunotherapy covers a wide range of tumor types and is safer than traditional radiotherapy and chemotherapy. However, its overall effective rate is only 20-40%. At present, there is a lack of relevant research clarifying whether the changes and clinical significance of the immune microenvironment in colorectal cancer patients with liver metastasis are conducive to enhancing the promotion and further improving the efficacy of immunotherapy.

Methods: We retrospectively collected the data of 50 colorectal cancer patients with liver metastasis treated in Chongqing University Cancer Hospital from January 2017 to January 2019. Liver metastatic cancer tissues and normal liver tissues were collected to detect the levels of immune cells in the two samples. At the same time, the correlation between T-cell subsets in the liver metastatic cancer tissue immune microenvironments of colorectal cancer patients and prognosis was analyzed.

Results: Compared with the normal liver tissues, the level of T helper cell 1/T helper cell 2 (Th1/Th2) in the liver metastatic cancer tissues was significantly decreased (0.88±0.24 vs. 1.34±0.27, P=0.000), while the levels of regulatory T cells were markedly increased (8.57±2.31 vs. 6.89±1.71, P=0.000). The Th1/Th2 level in liver metastatic cancer tissue exhibited a good predictive value for recurrence and survival 3 years after surgery, and the areas under the curves were 0.783 (95% confidence interval: 0.649-0.916, P=0.002) and 0.763 (95% confidence interval: 0.628-0.898, P=0.001), respectively. Moreover, the regulatory T-cell level in liver metastatic cancer tissue had a good predictive value for recurrence and survival at 3 years postoperatively, and the areas under the curves were 0.788 (95% confidence interval: 0.656-0.919, P=0.002) and 0.763 (95% confidence interval: 0.628-0.897, P=0.001), respectively.

Conclusions: The immunosuppressive condition of liver metastasis in colorectal cancer patients was related to poor prognosis.

Keywords: Colorectal cancer; immune microenvironment; liver metastasis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-1169/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Predictive value of the T helper cell 1/T helper cell 2 level in liver metastatic cancer tissues for the recurrence of patients 3 years after surgery.
Figure 2
Figure 2
Predictive value of the T helper cell 1/T helper cell 2 level in liver metastatic cancer tissues for the survival of patients 3 years after surgery.
Figure 3
Figure 3
Predictive value of the regulatory T-cell level in liver metastatic cancer tissues for the recurrence of patients 3 years after surgery.
Figure 4
Figure 4
Predictive value of the regulatory T-cell level in liver metastatic cancer tissues for the survival of patients 3 years after surgery.
See this image and copyright information in PMC

References

    1. Hirokawa F, Ueno M, Nakai T, et al. Treatment strategy for resectable colorectal cancer liver metastases from the viewpoint of time to surgical failure. Langenbecks Arch Surg 2022;407:699-706. 10.1007/s00423-021-02372-w - DOI - PubMed
    1. Lang H, Baumgart J, Roth W, et al. Cancer gene related characterization of patterns and point of recurrence after resection of colorectal liver metastases. Ann Transl Med 2021;9:1372. 10.21037/atm-21-292 - DOI - PMC - PubMed
    1. Tago T, Katsumata K, Udou R, et al. Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases. Anticancer Res 2021;41:5539-47. 10.21873/anticanres.15367 - DOI - PubMed
    1. Ho WW, Gomes-Santos IL, Aoki S, et al. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. Proc Natl Acad Sci U S A 2021;118:e2105323118. 10.1073/pnas.2105323118 - DOI - PMC - PubMed
    1. Sasaki K, Kobayashi S, Kudo M, et al. Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report. Surg Case Rep 2021;7:267. 10.1186/s40792-021-01346-w - DOI - PMC - PubMed